The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

The latest data identifies biohealth as a bright spot in VC funding for female founders, most significantly in the Northeast.

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and ...

The Swiss pharma will base cardiometabolic drug research at the new Allston site. Elsewhere, AskBio advanced a gene therapy ...

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Suki, the leader in artificial intelligence (AI) technology for healthcare, today expanded its partnership with Rush University System for Health, one of the nation's top academic health systems, to ...

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.